DNA origami structures have gained interest as carriers for drug delivery due to their biodegradability, low cytotoxicity, and ability to load diverse therapeutic molecules. They can enter cells and cross biological barriers, accumulating in solid tumors and showing potential for treating kidney injuries. Ligand molecules can be incorporated for active targeting. DNA origami structures offer customizable and precise drug delivery with minimal off -target effects. Smart carriers capable of sensing environmental stimuli and adapting their structures and properties are needed for effective drug delivery. DNA origami structures have been engineered as nanorobots with logic-gating capabilities, facilitating targeted delivery of drug molecules to specific cell types via conditional exposure. They can be unfolded selectively in tumor-associated blood vessels, promoting thrombosis and inhibiting tumor growth. DNA origami structures offer higher loading capacity and complex patterning compared to smaller DNA objects, making them advantageous for drug delivery. Challenges include stability in biological environments and immunogenicity, but these can be mitigated through rational engineering in well-folded DNA nanostructures. Furthermore, in fields such as cancer immunotherapy, DNA architectures with increased immunogenicity can be utilized as adjuvants. , .